Condition: COPD · Sponsor: Fisher and Paykel Healthcare
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.
This description comes directly from the study's public registry record.
Jenny Han · 64 9 574 0123 · optio2trial@fphcare.com
Always discuss trial participation with your own doctor first.
| The University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Central Iowa Hospital Corp - UnityPoint Health | Des Moines, Iowa, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| Temple University Hospital | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07222410